ADORA2A and Parkinson disease: Accordingly, it has been shown that specific A2AR antagonists attenuate motor impairment in a wide variety of PD models by reducing dopamine depletion, loss of dopaminergic neurons, production of reactive oxygen species, and aggregation of α-synuclein [218].